Quizartinib (AC220): Selective FLT3 Inhibitor for Acute Myeloid Leukemia Research

Executive Summary: Quizartinib (AC220) is a second-generation, highly selective inhibitor of FMS-like tyrosine kinase 3 (FLT3), with IC₅₀ values of 1.1 nM for FLT3-ITD and 4.2 nM for FLT3-WT, outperforming most other tyrosine kinase inhibitors in AML research (APExBIO). It exhibits over ten-fold selectivity for FLT3 compared to kinases such as PDGFRα, PDGFRβ, KIT, RET, and CSF-1R. Quizartinib blocks FLT3 autophosphorylation and downstream signaling pathways essential to AML cell proliferation. In vivo, oral dosing at 1 mg/kg significantly inhibits FLT3 activity and eradicates tumors in mouse xenograft models. Resistance mutations in FLT3 can emerge, underscoring the dynamic nature of AML pathogenesis (Song et al., 2025).

Biological Rationale

FLT3 is a receptor tyrosine kinase expressed in hematopoietic progenitor cells. Activating FLT3 mutations, especially internal tandem duplications (ITD), are present in approximately 30% of acute myeloid leukemia (AML) cases and associate with poor prognosis (APExBIO). FLT3-ITD leads to constitutive activation of downstream signaling pathways, promoting proliferation and survival of AML cells. Targeting aberrant FLT3 activity with selective inhibitors is a validated strategy for preclinical AML research (Quizartinib (AC220): Selective FLT3 Inhibitor for AML Res...). This article extends previous coverage by including recent pharmacokinetic and resistance data, providing a comprehensive experimental perspective.

Mechanism of Action of Quizartinib (AC220)

Quizartinib (AC220) binds to the ATP-binding pocket of FLT3, inhibiting both wild-type and ITD-mutated forms. It blocks FLT3 autophosphorylation, thereby shutting down FLT3-dependent downstream signaling cascades, including the PI3K/AKT and MAPK pathways. This inhibition halts AML cell proliferation and induces apoptosis. Quizartinib displays an IC₅₀ of 1.1 nM for FLT3-ITD and 4.2 nM for FLT3-WT under standard in vitro assay conditions (10% FBS, 37°C, 24h incubation) (APExBIO). The selectivity profile indicates at least a ten-fold lower affinity for other kinases such as PDGFRα, PDGFRβ, KIT, RET, and CSF-1R, minimizing off-target effects.

Evidence & Benchmarks

• Quizartinib (AC220) inhibits FLT3-ITD and FLT3-WT with IC₅₀ values of 1.1 nM and 4.2 nM, respectively (APExBIO, product data).
• In MV4-11 and RS4;11 AML cell lines, Quizartinib suppresses FLT3 signaling and cell proliferation at low nanomolar concentrations (APExBIO).
• Oral administration at 1 mg/kg in mouse xenograft models significantly inhibits FLT3 activity, extends survival, and can eradicate FLT3-dependent tumors (Song et al., 2025).
• Maximum plasma concentration (Cmax) of 3.8 μM is achieved within 2 hours post-oral dosing in preclinical pharmacokinetic studies (APExBIO, product data).
• Quizartinib demonstrates ≥28.03 mg/mL solubility in DMSO but is insoluble in ethanol and water (APExBIO).
• Resistance mutations in FLT3, such as D835Y, can develop during extended use, reducing efficacy and highlighting the need for resistance modeling (Quizartinib (AC220): Advanced FLT3 Inhibition...).

Applications, Limits & Misconceptions

Quizartinib (AC220) is optimized for:

• In vitro FLT3 autophosphorylation inhibition assays in AML research.
• In vivo studies using FLT3-driven mouse xenograft models.
• Translational research on resistance mechanisms and next-generation FLT3-targeted therapies (Quizartinib (AC220): Mechanistic Precision...). This article updates earlier perspectives by emphasizing validated pharmacokinetic and resistance benchmarks.

Common Pitfalls or Misconceptions

• Quizartinib is not suitable for kinases with high sequence homology to FLT3 unless selectivity is empirically confirmed.
• It is not intended for diagnostic or therapeutic use in humans—research use only (APExBIO).
• Long-term storage of solutions is not recommended due to potential loss of activity; use freshly prepared solutions.
• Resistance mutations in FLT3 (e.g., D835Y) can abrogate Quizartinib efficacy, requiring alternative or combination approaches (Pioneering the Next Chapter of FLT3-Targeted Research...). This extends earlier summaries by enumerating specific resistance boundaries.
• Solubility limitations: insoluble in ethanol and water; only use DMSO as solvent at recommended concentrations.

Workflow Integration & Parameters

Quizartinib (AC220) is supplied as a solid and should be stored at -20°C. For use, dissolve in DMSO at concentrations up to 28.03 mg/mL. Do not store solutions long-term; prepare fresh aliquots for each experiment. In vitro assays typically use 1–100 nM concentrations in 10% FBS, 37°C, 24h incubation conditions. For in vivo studies, oral dosing at 1–10 mg/kg in mouse models is standard, with Cmax reached within 2 hours post-administration. Safety and pharmacokinetic profiles are favorable in preclinical species (APExBIO).

Conclusion & Outlook

Quizartinib (AC220) represents a best-in-class tool for selective FLT3 inhibition in AML research, enabling precise modulation of FLT3 signaling and resistance modeling. Its nanomolar potency and in vivo efficacy are well validated. However, resistance mutations in FLT3 require ongoing mechanistic studies and combination therapy exploration. For further guidance on experimental design and next-generation FLT3-targeted studies, see Quizartinib (AC220) and the Future of FLT3 Inhibition..., which this article complements by focusing on experimental parameters and current resistance findings. For ordering and detailed specifications, visit the Quizartinib (AC220) product page from APExBIO.